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Corticosteroids in idiopathic pulmonary fibrosis
Joseph P. Lynch III, MD, Eric White, MD, and Kevin Flaherty, MD
Corticosteroids were the mainstay of therapy for idiopathic
pulmonary fibrosis (IPF) for more than four decades, but their
efficacy is unproven and toxicities are substantial. The course
of IPF is characterized by progressive respiratory insufficiency,
leading to death within 3 to 8 years from the onset of
symptoms. Although a subset (10–20%) of patients survives
more than 10 years, there is no evidence that any form of
therapy alters the natural history of the disease. Nonetheless,
given the poor prognosis, a trial of corticosteroids is often
given. Because of the rarity of IPF, randomized,
placebo-controlled therapeutic trials have not been done.
Further, no studies have compared differing dosages or
duration of corticosteroid in matched patients. Interpretation of
therapy efficacy is obscured by several factors including
heterogeneous patient populations, inclusion of patients with
histologic entities other than usual interstitial pneumonia, lack
of objective, validated endpoints, different criteria for
“response.” We review published data regarding
corticosteroid therapy for IPF and present a rationale for
stratifying therapy based on host, demographic, and clinical
factors that influence prognosis as well as risk for
corticosteroid complications. Curr Opin Pulm Med 2001, 7:298–308
© 2001 Lippincott Williams & Wilkins, Inc.
Corticosteroids (CS) have been the mainstay of therapy
for idiopathic pulmonary fibrosis (IPF) for more than
four decades [1–3], but their efficacy is unproven [4••,5–
7] and toxicities are substantial [4••,8••]. The terms IPF
and cryptogenic fibrosing alveolitis (CFA) are synony-
mous [3,9,10]. A recent international consensus state-
ment concluded “usual interstitial pneumonia (UIP) is
the histopathologic pattern that identifies patients with
IPF” [3]. Other histologic patterns have a better prog-
nosis and higher rate of response to CS than UIP and are
considered distinct entities [3]. Cardinal features of
IPF/CFA include dry cough, exertional dyspnea, end-
inspiratory Velcro rales, diffuse parenchymal infiltrates
on chest radiographs, honeycomb cysts, a restrictive de-
fect on pulmonary function tests (PFT), impaired gas
exchange, and impaired oxygenation (Table 1) [3,10–12].
The course is indolent but inexorable with progressive
respiratory failure [13]. Fewer than 40% survive 5 years;
the mean survival is 2.8 to 3.6 years [4••,5,7,14–17]. Be-
cause IPF/CFA is rare (estimated prevalence rates of
three to 20 cases per 100,000 population) [3,12,18,19],
randomized, placebo-controlled therapeutic trials have
not been done. CS are most often used, but dose, rate of
taper, and duration differ among studies [1,2,10,20–22].
Interpretation of published data is misleading because
patients with histologic entities other than UIP (and that
have a better prognosis than UIP) were included in ear-
lier reports of IPF/CFA.
Definition of idiopathic pulmonary fibrosis
Historically, the histologic lesion UIP was considered to
represent a subset of patients with IPF [23,24]. Current
recommendations restrict the term IPF to patients with
idiopathic UIP [3]. Other types of idiopathic interstitial
pneumonia (IIP) include desquamative interstitial pneu-
monia (DIP) [24,25], respiratory bronchiolitis interstitial
lung disease (RBILD) [25], nonspecific interstitial
pneumonia/fibrosis (NSIP) [14,15,17,26,27], acute inter-
stitial pneumonia [28,29], lymphoid interstitial pneumo-
nia [30], and cryptogenic organizing pneumonia, also
termed bronchiolitis obliterans organizing pneumonia
[31]. These types of IIP have a better prognosis and
higher rates of response to CS compared with UIP. A
definitive diagnosis of UIP requires surgical (open or
video-assisted thoracoscopic lung biopsy) [3,25], but the
diagnosis of UIP can be confirmed with confidence by
thin-section high-resolution computed tomography
(HRCT) scans in some patients [27,32]. Most published
series of IPF or CFA likely incorporated a mixture of
histologic entities [1,2,20–23,33,34]; it is plausible that
most steroid-responsive cases of IPF represented disor-
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Abbreviations
AZA azathioprine
CFA cryptogenic fibrosing alveolitis
CS corticosteroids
DIP desquamative interstitial pneumonia
ECM extracellular matrix
GGO ground glass opacities
HRCT high-resolution computed tomography
IIP idiopathic interstitial pneumonias
IPF idiopathic pulmonary fibrosis
NSIP nonspecific interstitial pneumonia
PFT pulmonary function test
RBILD respiratory bronchiolitis interstitial lung disease
UIP usual interstitial pneumonia
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ders other than UIP. When the diagnosis of UIP is sub-
stantiated, response to therapy is poor and mortality is
high [14,15,17,27].
Histopathologic features of usual
interstitial pneumonia
The cardinal histopathologic features of UIP include bi-
lateral but heterogeneous (patchy) involvement, a predi-
lection for the lower lobes and peripheral (subpleural)
regions, fibroblastic foci (aggregates of proliferating fi-
broblasts and myofibroblasts), excessive collagen and ex-
tracellular matrix (ECM), and honeycomb cysts [3,25].
Mononuclear cell infiltrates (eg, lymphocytes, plasma
cells, macrophages) and scattered neutrophils and
eosinophils may be present within alveolar septa, but
inflammatory changes are not conspicuous [25]. The het-
erogeneity of the histologic lesion can be seen at
low-power magnification; areas of normal lung interstitial
inflammation, fibrosis, and honeycomb cysts are ob-
served concomitantly [3,25]. Additional features of UIP
include traction bronchiectasis and bronchiolectasis, re-
duced airspace volume, destroyed or distorted alveolar
architecture, smooth muscle hypertrophy, reactive meta-
plasia and hyperplasia of type II pneumocytes, mucosta-
sis, and secondary pulmonary hypertensive changes
[17,25].
Which histologic features differentiate usual
interstitial pneumonia from other idiopathic
interstitial pneumonias?
Temporal heterogeneity is the central feature that dis-
tinguishes UIP from other types of IIP [14,15,17,25]. Fi-
broblastic foci and honeycomb cysts are prominent fea-
tures of UIP but are absent or inconspicuous in other
types of IIP [25]. Inflammatory cells are not prominent in
UIP in contrast to cellular NSIP, DIP, or hypersensitivity
pneumonia [25]. Despite the gold standard status of
open lung biopsies [25], evaluation is subject to interob-
server and intralobar variation, even by expert pulmo-
nary pathologists [35••,36]. Discriminating UIP from fi-
brotic NSIP is difficult [35••,36]. Further, surgical lung
biopsy is expensive and carries significant morbidity and
even mortality [37,38]. In clinical practice, open (or
video-assisted thoracoscopic surgical) biopsies are per-
formed in only 10 to 30% of patients with IPF [7,11,12].
Since the advent of HRCT scans, many clinicians rely on
them to corroborate the diagnosis of UIP [3,4••,27,39].
High-resolution computed tomography
High-resolution CT scans, using 1- to 2-mm thin sec-
tions, are often used in lieu of surgical lung biopsies to
diagnose UIP [3,14,27,40,41]. Provided HRCT features
are classical, the accuracy of a confident diagnosis of UIP
on HRCT by a trained observer is greater than 90%
[3,42,43]. However, a confident diagnosis of UIP can be
made in less than two thirds of patients with histologic
UIP [3,43]. Inter- and intraobserver variability can be
problematic for inexperienced radiologists, particularly
in less severe cases [44].
What are the salient high-resolution computed
tomography features that allow a confident
diagnosis of usual interstitial pneumonia?
Characteristic HRCT features of UIP include a distinct
predilection for the basilar and peripheral (subpleural)
regions of the lungs, patchy involvement, large areas of
spared lung parenchyma, coarse reticular or linear opaci-
ties (intralobular and interlobular septal lines), honey-
comb cysts, and traction bronchiectasis or bronchiolecta-
sis [15,27,39,45,46]. Focal areas of ground glass opacities
(GGO) are sometimes present in UIP [15,45,47,48], but
extensive areas of GGO suggest an alternative diagnosis
(eg, DIP, NSIP, hypersensitivity pneumonia) [3]. Hon-
eycomb cysts are a cardinal feature of UIP [15,34,
39,45,47] but are rare in other types of IIP [15,25,27].
How reliable is high-resolution computed
tomography in assessing prognosis or
responsiveness to therapy?
The extent and pattern of changes on HRCT are invalu-
able in assessing prognosis and responsiveness to therapy
[27,34,45,46,49–51]. GGOmay reflect alveolar inflamma-
tion, intraalveolar granulation tissue, or fibrosis of intra-
lobular and alveolar septa [39,45,46,52]. A reticular pat-
tern reflects fibrosis, but inflammation may coexist
[39,45,51,53]. Honeycomb cysts indicate irreversible de-
struction of alveolar walls and fibrosis [34,45,48,49,53–
55]. A pattern of predominant GGO on HRCT predicts
a higher likelihood of response to CS therapy and im-
proved survival compared with reticular or honeycomb
patterns [34,46,50,51,55–57]. After CS therapy, GGO re-
gress in 30 to 44% of patients [34,39,55]; however, GGO
may progress to irregular reticular opacities or honey-
comb cysts [34,39,51,53]. Reticular patterns or honey-
comb cysts never improve and may worsen over time
[34,39,45,53,55]. Most patients with IPF display mixed
patterns [34,55]. In published series of IPF/CFA, ap-
proximately 10% of patients had predominantly GGO on
Table 1. Characteristic features of usual interstitial pneumonia
Category Features
Clinical Dry cough, exertional dyspnea
Physical exam End-inspiratory rales, clubbing
High-resolution CT Patchy involvement, course reticular/linear
opacities, honeycomb cysts,
basilar/subpleural involvement, traction
bronchiectasis
Pulmonary function Reduced lung volume, reduced diffusing
capacity for carbon monoxide,
hypoxemia, increased alveolar-arterial
oxygen difference
Histopathologic Heterogeneous distribution, fibroblastic
foci, excessive collagen and
extracellular matrix, honeycomb cysts
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HRCT [34,55], but surgical lung biopsies were not per-
formed in many patients. It is likely that patients with
predominant GGO had diseases other than UIP (eg, DIP,
NSIP, hypersensitivity pneumonia). Further, the long-
term impact of CS on altering the natural history of
IPF/CFA is not known. Japanese investigators retrospec-
tively reviewed serial CT scans of 29 patients with IPF
(17 were treated with CS) [53]. Although GGO initially
decreased with therapy, progression to honeycomb cysts
ensued in 90% of patients.
Extensive fibrosis (reticulation or honeycomb cysts) on
HRCT is a poor prognostic sign. Gay et al. [49] prospec-
tively studied 38 patients with IPF to identify pretreat-
ment variables that could predict response to CS therapy
and long-term survival. Open or video-assisted thoraco-
scopic surgical lung biopsies and CT scans were quanti-
tatively scored. Pretreatment CT alveolar (CT-alv) and
fibrotic (CT-fib) scores predicted responsiveness to
therapy and mortality. Responders to prednisone therapy
had higher CT-alv scores and lower CT-fib scores com-
pared with nonresponders or the stable group. Survivors
had higher CT-alv and lower CT-fib scores compared
with those who died during follow-up. Severe fibrosis on
pretherapy HRCT (CT fibrosis score  2) predicted
mortality with 80% sensitivity and 85% specificity [49].
HRCT was a better predictor of survival than pulmonary
function tests (PFT), clinical/radiographic/physiologic
scores, or pathologic scores (from surgical lung biopsies).
Pathogenesis of usual
interstitial pneumonia
The pathogenesis of UIP is unclear, but epithelial cell
injury, destruction of subepithelial basement membrane,
recruitment and proliferation of fibroblasts, and exces-
sive deposition of extracellular matrix (ECM) and colla-
gen are pivotal in orchestrating the fibrotic process
[58••]. Early hypotheses emphasized sustained alveolar
inflammation [59,60] as a precursor to fibrosis. Activated
alveolar macrophages, lymphocytes, and neutrophils
were considered the immune effector cells driving the
inflammatory process [59], leading to repetitive lung in-
jury and fibrosis [61]. However, there is little evidence to
support this hypothesis, and the relevance of chronic
inflammation to the development of fibrosis is not clear
[62]. Recent studies underscore the importance of fibro-
blasts, myofibroblasts, abnormal ECM deposition, and
myriad cytokines and soluble factors in the pathogenesis
of UIP [58••].
Injury of alveolar epithelial cells and destruction of sub-
epithelial basement membranes appear to be key events
in the pathogenesis of UIP [62,63]. After lung injury,
fibroblasts migrate and proliferate into the alveolar septa
and spaces [62,64]. Areas of rapidly proliferating myofi-
broblasts and fibroblasts (fibroblastic foci) [65] are the
primary sites of ongoing injury and repair, leading to
collagen deposition [62]. Transforming growth factor 1
stimulates fibroblast proliferation and differentiation into
myofibroblasts, stimulates synthesis of collagen and
ECM proteins, inhibits synthesis of proteases that de-
grade the ECM, and likely plays a pivotal role in orches-
trating fibrogenesis in UIP [62,66]. Fibroblasts and myo-
fibroblasts from patients with UIP induce apoptosis and
necrosis of alveolar epithelial cells in vitro [62,67]. Alveo-
lar epithelial shedding, in turn, releases transforming
growth factor 1 from ECM, which promotes myofibro-
blast production of collagen [68]. Fibroblasts from pa-
tients with UIP demonstrate enhanced production of col-
lagens [58••], increased expression of tissue inhibitors of
metalloproteinases, and a relative decrease in collage-
nases [62,69]; all these processes promote the formation
of scar.
Alveolar macrophages elaborate profibrotic cytokines (eg,
platelet-derived growth factor [70], insulin-like growth
factor I [71], interleukin-1 [72]), ECM proteins [70], and
free oxygen radicals [73], which may be important in the
pathogenesis of UIP.
Production, deposition, and proteolysis of ECM are criti-
cal to pulmonary remodeling, repair, and development of
fibrosis. ECM proteins (eg, tenascin [65,74], fibronectin
[58••], collagen [75]) are expressed in increased amounts
in UIP. In the initial phases, both type III and I collagen
accumulate; later, type I predominates [75]. Type I col-
lagen reflects irreversible fibrosis attributable to greater
resistance to metalloproteinase digestion [62]. Tenascin,
another ECM protein, is present in increased amounts in
UIP [65] and may correlate inversely with survival [74].
Another ECM protein, fibronectin may be important in
the pathogenesis of UIP. Fibronectin acts as a growth
factor and chemoattractant for fibroblasts [62,76]. In one
study, alveolar macrophages from patients with UIP pro-
duced fibronectin at a rate 20 times higher than normal
alveolar macrophages [77]; this may promote local re-
cruitment of fibroblasts and collagen deposition, promot-
ing local fibrosis.
Angiogenesis and the production of angiogenic factors by
host cells likely contribute to the pathogenesis of UIP.
Neovascularization may promote fibrogenesis [62], per-
haps by supplying blood to rapidly proliferating fibro-
blasts within fibroblastic foci. Chemokines (chemotactic
cytokines) may promote fibrosis in patients with IPF
[78]. Other angiogenic molecules, such as vascular endo-
thelial growth factor and acidic and basic fibroblast
growth factor may be involved in the pathogenesis of
UIP, but data are lacking [78].
Other molecules believed to play some role in the patho-
genesis of UIP include interleukin-1 receptor antagonist
300 Interstitial lung disease
[79], integrin-mediated adhesion molecules [80], surfac-
tant proteins [81], and oxidants [82]. In summary, alveo-
litis and chronic inflammation likely play roles in the
pathogenesis of UIP, but their importance is probably
minor [62]. The most critical factors orchestrating the
fibrotic process are altered fibroblast phenotype and in-
teractions between immune and nonimmune cells,
which lead to profibrotic cytokines. Elucidating the
mechanisms of fibrosis in UIP will facilitate the devel-
opment of novel, targeted therapies for this devastating
disease.
Therapy of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis/cryptogenic fibrosing al-
veolitis is a frustrating disease to treat because the dis-
ease progresses inexorably in most patients, regardless of
therapy [13]. Historically, CS or immunosuppressive or
cytotoxic agents were used to treat IPF in an attempt to
ablate any inflammatory component. However, large ret-
rospective studies found no survival benefit with any
form of therapy [3,4••,5,6]. Despite the lack of proven
efficacy, CS therapy is offered in 39 to 66% of patients
with IPF; treatment is often withheld in the elderly be-
cause of concern about adverse effects [4••,5–7,11]. In
one clinical survey, 61% of IPF patients younger than
age 70 were treated with CS compared with only 28% of
patients older than age 70 [7]. Immunosuppressive or
cytotoxic agents were used in only 2 to 17% of patients
(primarily in patients failing or experiencing adverse ef-
fects from CS [4••,5,7,11]. Anecdotal responses were
cited with cytotoxic agents (eg, azathioprine [AZA], cy-
clophosphamide)[2,20–22,33,83], but the efficacy of
these agents is unproven [4••,5,6,21,84,85]. Similarly,
colchicine [4••,86] and D-penicillamine [87] have been
used to treat IPF/CFA but are of unproven benefit. In
1995, Hunninghake and Kalica [88], summarizing a
working conference on IPF convened by the National
Heart, Lung, and Blood Institute (NHLBI) in 1994
noted that “there was a general consensus at the work-
shop that pulmonary fibrosis is a highly lethal lung dis-
order and that current therapies for this disease have
little effect on the natural history of the disease.” In
1999, a summary of a 1998 NIHLBI workshop on IPF
arrived at a similar conclusion: “…these observations
suggest that current therapy has minimal or no beneficial
effect for patients with IPF” [89]. More recently, a re-
cent International Consensus Statement concluded “no
data exist that adequately document any of the current
treatment approaches improves survival or the quality of
life for patients with IPF” [3]. These conclusions are
sobering and suggest that novel therapies are essential to
improve the prognosis of this fatal disorder [88,89]. In
this review, we focus on the role (if any) of CS to treat
IPF/CFA. A discussion of other potential therapies for
IPF/CFA is beyond the scope of this paper and is ad-
dressed only briefly.
Impact of corticosteroids in idiopathic pulmonary
fibrosis: results of retrospective studies
The largest series of UIP comprised 487 patients seen at
the Mayo Clinic from 1994 to 1996 [4••]. The diagnosis
of UIP was confirmed by open lung biopsies in 20% and
by HRCT in 80%. Median survival was 3.2 years from
the time of diagnosis. Efficacy of therapy was evaluated
retrospectively by a review of clinical records. Treatment
regimens included prednisone alone in 54, colchicine
plus prednisone in 71, colchicine alone in 167, other
treatment in 38, and no therapy in 154. By univariate
analysis, the use of prednisone or prednisone plus col-
chicine was associated with a worse survival compared
with no therapy. On multivariate analysis, older age,
male gender, lower diffusing capacity for carbon monox-
ide (DLCO), and a history of worsening lung function
were associated with worse survival. When these factors
were taken into account, survival among patients receiv-
ing prednisone was similar to untreated patients. An-
other retrospective study of 244 patients with CFA cited
higher mortality rates among patients treated with either
CS or cyclophosphamide [5]. Mean survival was 3.6 years
for prevalent cases and 2.3 years for incident cases. CS
were used in 47% of 76 incidence cases and 65% of 168
prevalent cases. Odds ratio (OR) for mortality was worse
among prednisone-treated patients, both in the incident
cohort (OR: 2.01) and prevalence cohort (OR: 2.08). The
worse survival among patients treated with CS likely re-
flects selection bias because sicker patients were prob-
ably treated more aggressively. A prospective survey
from 1991 to 1992 in England, Scotland, and Wales iden-
tified 588 patients with a new diagnosis of CFA [12].
Open lung biopsies were done in only 12.4%. No treat-
ment was offered in 48%; the remaining patients were
treated with CS and immunosuppressive or cytotoxic
drugs. By October 1994, 45% of patients had died; the
impact of treatment was not determined. A retrospective
review of 234 patients with UIP (confirmed by open lung
biopsies or autopsies) from Japanese hospitals cited simi-
lar mortality rates among untreated patients compared
with patients treated with CS [6].
Several early studies of patients with IPF/CFA cited re-
sponse rates of 10 to 30% with CS (alone or combined
with immunosuppressive agents) [1,2,20–22,33,83,84],
but complete or sustained remissions were rare. Two
studies in the mid-1980s cited beneficial responses to
high-dose CS in patients with IPF/CFA with lymphocy-
tosis on bronchoalveolar lavage [22,33]. These various
published series of IPF or CFA failed to classify patients
according to histologic entities (eg, UIP, DIP, NSIP) and
cannot be extrapolated to UIP. It is plausible that ste-
roid-responsive patients had cellular NSIP (or some
other IIP) and not UIP. Retrospective reviews of open
lung biopsies previously labeled as IPF or CFA revealed
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that only 47 to 71% of cases were UIP, 13 to 36% were
reclassified as NSIP, and the remaining patients were
categorized as DIP, RBILD, or miscellaneous [14,15,17,
27,35••,36]. Compared with other types of IIP, UIP ex-
hibits considerably lower survival rates and responsive-
ness to therapy [14,15,17,27,35].
What is the response to corticosteroids among idiopathic
pulmonary fibrosis patients in prospective
randomized trials?
A few randomized therapeutic trials compared CS with
immunosuppressive or cytotoxic agents [20,21,23,90] or
colchicine [40] as therapy for IPF. These studies did not
subclassify patients as UIP. One 6-month study at the
National Institutes of Health randomized 28 patients
with mid-course IPF to prednisone alone (n = 16), pred-
nisone plus oral CP (n = 9), or CP alone (n = 5) [90]. At
6 months, PFT or chest radiographs did not change in
any group. Another prospective trial in England random-
ized 43 patients with untreated IPF to high-dose pred-
nisolone alone (60 mg/d with gradual taper) or oral CP
plus low-dose prednisolone (20 mg every other day) [21].
Symptoms, chest radiographs, and PFT were monitored
as endpoints. Seven of 22 patients (31%) receiving pred-
nisolone alone showed initial improvement. At 3 years,
only two patients treated with prednisolone alone main-
tained improvement, and 15 had worsened (10 deaths).
Two prospective studies evaluated high-dose predniso-
lone plus AZA for IPF [20,23]. In the first study, 20
patients with progressive IPF were treated with high-
dose prednisone alone for 3 months [23]. At 3 months,
AZA, 3 mg/kg/d, was added, and both agents were con-
tinued for an additional 9 months or longer. Overall, 12
patients (60%) improved (defined as increase in vital ca-
pacity 20% above baseline) but the concomitant use of
AZA obscures the effect of prednisone. In a second,
double-blind trial by these investigators, 27 patients with
newly diagnosed IPF were randomized to receive AZA
plus high-dose prednisone, 1.5 mg/kg/d, with taper (n =
14) or high-dose prednisone plus placebo (n = 13) [20].
At 1 year, four patients died in each group. Changes in
PFT were minimal and were similar between groups. At
1 year, vital capacity improved (>10% above baseline) in
three of 13 patients receiving prednisone alone; DLCO
improved (> 20% above baseline) in only two patients. At
long-term follow-up (at a mean of 9 years), 77% in the
prednisone plus placebo cohort had died (compared with
43% of AZA-treated patients). This survival difference
was not statistically significant (P = 0.16). Investigators at
the Mayo Clinic randomized 26 patients with idiopathic
UIP to colchicine (0.6 mg once or twice daily) (n = 14) or
high-dose prednisone (n = 12) [40]. PFT did not improve
in any subject in either group. Side effects were more
frequent and severe in the prednisone cohort. A prospec-
tive but nonrandomized study from Mexico evaluated
four patient cohorts with IPF [87]. Treatment regimens
included colchicine plus prednisone (n = 19); D-
penicillamine plus prednisone (n = 11); prednisone plus
colchicine plus D-penicillamine (n = 11) or prednisone
alone (n = 15). Five-year mortality was 52% and did not
differ between treatment groups [87]. We recently pub-
lished our experience of 41 patients with IPF treated
with high-dose CS (1 mg/kg/d, with taper) [8••]. Eleven
patients (27%) improved (defined by  10-point drop in
clinical/radiographic/physiologic scores); 19 (46%) re-
mained stable; 11 (27%) deteriorated. Survival was im-
proved among patients who remained stable or re-
sponded to therapy compared with nonresponders.
However, additional factors independently affected sur-
vival (eg, extent of fibrosis on CT or lung biopsy). Im-
portantly, on review of open lung biopsies (initially di-
agnosed as UIP), most steroid-responsive patients had
NSIP and not UIP.
What is the response to corticosteroids among patients
with a histologic diagnosis of usual interstitial pneumonia?
When the diagnosis of UIP is confirmed by surgical lung
biopsies, survival and response rates (to any form of
therapy) are dismal (0–16%) [14,15,24,27,35••,45,54,91].
Most data are gleaned from retrospective studies. A ret-
rospective review of open lung biopsies at the Mayo
Clinic from 1976 to 1985 identified 63 patients with UIP
[14]. Although data regarding therapy were not provided,
89% were treated with CS. Median survival (entire co-
hort) was 2.8 years; only 20% survived 5 years. Another
study from the Mayo Clinic retrospectively compared 22
patients with UIP treated with prednisone alone with 22
patients with UIP treated with colchicine alone [86]. Vi-
tal capacity improved to more than 15% above baseline
in only one of 22 receiving prednisone. Japanese inves-
tigators cited a 7-year survival rate of 23% among 64
patients with UIP [15]. None of 30 patients treated with
CS improved [15]. In a recent retrospective British study
[27], 13 patients with UIP were treated with CS or im-
munosuppressive agents (alone or in combination). Only
one improved (7%); the mean survival was 2.7 years. In
another retrospective study, these investigators analyzed
37 patients with UIP (confirmed by open lung biopsies)
[35••]. Twenty-eight patients were treated with CS
(alone or with immunosuppressive agents); only three
(11%) responded. At 42 months, only four patients (11%)
were alive [35••]. A retrospective review of open lung
biopsies from the National Institutes of Health detected
56 cases of UIP [17]. Five- and 10-year survival rates for
UIP were 43 and 15%, respectively. Data regarding
therapy were not provided. These data suggest that ear-
lier studies of IPF/CFA citing response rates of as high as
30% likely included a mix of histologic lesions other than
UIP.
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Steroid responders may represent histologic subsets other
than usual interstitial pneumonia (eg, nonspecific
interstitial pneumonia, desquamative interstitial
pneumonia/respiratory bronchiolitis interstitial lung
disease, chronic hypersensitivity pneumonia)
In contrast to the dismal response rates to CS observed
with UIP, steroid responsiveness and survival are sub-
stantially better among patients with other types of IIP
( e g , NSIP [14,15 ,27 ,35••,91] or DIP/RBILD
[14,17,24,25,92]. Prognosis of DIP/RBILD is generally
excellent (with or without CS therapy), with survival
rates as high as 90% at 10 years [14,17,24,25]. The prog-
nosis of NSIP is less well established, but retrospective
studies cite 5- and 10-year survival rates exceeding 70%
in some series [14,15,27,35••,91]. Further, a significant
proportion (45–83%) with cellular NSIP respond to CS
therapy [15,25,93,94]; the prognosis for fibrotic NSIP is
worse (response rates to CS as low as 30%; < 50% 5-year
survival) [35••]. Previous reports of steroid-responsive
IPF/CFA correlating with GGO on HRCT [34,46,50,51,
55–57] or bronchoalveolar lavage lymphocytosis [22,33]
may reflect inclusion of histologic entities other than
UIP (eg, NSIP, RBILD, chronic hypersensitivity pneu-
monia). Although data are limited, we believe CS are
warranted for NSIP or cases of DIP/RBILD with persis-
tent symptoms or pulmonary dysfunction despite cessa-
tion of cigarette smoking [92].
Complications of corticosteroid therapy
Corticosteroid therapy is associated with myriad adverse
effects that are related to both the dose and duration of
treatment [95,96]. Side effects of CS can be debilitating
and include musculoskeletal complications (vertebral
compression fractions, aseptic necrosis of femoral and
humeral heads, osteoporosis, myopathy), neuropsychiat-
ric effects (psychosis, depression, irritability; insomnia,
inappropriate euphorias), endocrine and metabolic alter-
ations (hyperglycemia, metabolic alkalosis, salt and water
retention), opportunistic infections, weight gain, truncal
obesity, Cushingoid features, peptic ulcer disease, exac-
erbation of hypertension, posterior capsular cataracts;
menstrual irregularities. The use of CS to treat any dis-
ease requires a careful assessment of potential risks and
potential benefits associated with therapy. This certainly
applies to IPF/UIP, where the efficacy of CS therapy is
unproven. The risk of CS therapy may outweigh the
benefit in populations at increased risk of CS adverse
effects (eg, age > 70 years, extreme obesity, osteoporosis,
diabetes mellitus, underlying psychiatric disorder). CS
effects may be devastating in the elderly [7,8••,40].
A recent study of 374 patients receiving oral CS for vari-
ous lung diseases cited a significant increased rate of
complications compared with control subjects not receiv-
ing CS [95]. There was a higher incidence of fractures,
muscle weakness, back pain, bruising, oral candidiasis,
use of histamine-2 antagonists, and cataracts among CS-
treated patients. The effects of CS were dose depen-
dent. The frequency of CS-associated adverse effects is
high among patients with IPF, many of whom are elderly
or have comorbidities [8••,40,97]. When questionnaires
were done prospectively to assess CS effects among pa-
tients with IPF, adverse effects were nearly invariably
observed [8••,40]. Douglas et al. [40] prospectively ana-
lyzed side effects among 12 IPF patients treated with
high-dose CS. The most commonly reported side effects
included Cushingoid features (75%), diabetes mellitus
(50%), insomnia (50%), myopathy (42%), muscle cramps
(42%), depression (25%), and epigastric pain (25%).
Similarly, we prospectively evaluated 41 IPF patients
treated with a 3-month course of high-dose CS [8]. All 41
patients experienced at least one complication of CS dur-
ing the first 3 months of treatment. The frequency of
these complications is shown in Table 2. Although CS
benefits some patients, the high incidence of adverse
effects underscores the need to stratify risk for CS com-
plications when treatment is being contemplated. In the
following sections, we discuss ways to minimize the risk
of CS adverse effects.
Osteoporosis
Osteoporosis is a well-recognized complication of CS and
can lead to fractures [98]. Potential mechanisms by
which CS lead to bone loss and osteoporosis include de-
creased production of testosterone, decreased calcium
absorption, increased calcium excretion, and decreased
Table 2. Selected side effects during 3 months of high-dose
steroid therapy in 41 patients with idiopathic
pulmonary fibrosis
Category Patients, n (%)
Psychological
Irritability 25 (61)
Insomnia 31 (76)
Depression 15 (37)
Musculoskeletal
Spontaneous fracture 2 (5)
Avascular necrosis 2 (5)
Infection
Local 11 (27)
Systemic 9 (22)
Gastrointestinal
Abdominal bloating 14 (34)
Peptic ulcer 1 (2)
Endocrine/metabolism
Glucose impairment 10 (24)
Hypertension 3 (7)
Weight gain 29 (71)
Edema 17 (41)
Muscle cramping 15 (37)
Fatigue 12 (32)
Dermatologic
Cushingoid change 30 (73)
Acne 11 (27)
Easy bruising (echymosis) 13 (32)
All patients experienced at least one side effect. Adapted with
permission [8].
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production of osteocalcin by osteoblasts [99]. Simple
nonpharmacologic measures advocated to reduce bone
loss include (1) increasing activity, (2) maintaining good
nutrition, (3) refraining from smoking, and (4) modulat-
ing consumption of alcohol [99]. Supplemental calcium
and vitamin D are recommended for patients receiving
CS, but this strategy does not consistently prevent os-
teoporosis in high-risk patients. The risk of fractures is
increased considerably among patients receiving high-
dose CS. In a recent study, the risk of hip fracture over
4 years was doubled in patients taking oral CS compared
with that of controls [100]. In another study of 367 pa-
tients taking CS for diverse lung diseases, the cumula-
tive incidence of fractures (all sites) was 23% for patients
receiving oral CS compared with 15% in controls not
receiving CS (OR: 1.8) [95]. More important, among CS-
treated patients, the risk of fractures was markedly in-
creased (compared with controls) at the following sites:
vertebrae (OR: 10), hips (OR: 6), and ribs or sternum
(OR: 3.2).
Measurement of bone mineral density (BMD) is recom-
mended as a proxy measure of bone strength and to
assess the risk of fracture [98]. Baseline BMD should be
measured in patients receiving long-term CS treatment,
particular in the elderly or postmenopausal women [98].
Pharmacologic therapy should be considered for patients
with BMD 1 to 2 SD below normal or for patients with a
history of fracture [99]. Calcium and vitamin D have
been used for many years for the treatment of osteopo-
rosis. A recent meta-analysis demonstrated a clinically
and statistically significant prevention of bone loss from
the lumbar spine and forearm with calcium and vitamin
D in CS-treated patients [101]. Those authors recom-
mended prophylactic therapy with calcium and vitamin
D for all patients who are being started on CS [101]. This
recommendation is most appropriate for patients with
low dietary calcium intake (< 1.0–1.5 g/d) and without
contraindications to supplemental calcium (eg, renal cal-
culi) [99]. Patients with a history of fracture or baseline
osteoporosis should be given bisphosphonates (eg, alen-
dronate, risedronate) [102] because these agents are ben-
eficial in treating and preventing CS-induced osteoporo-
sis [99,103–105]. A recent meta-analysis including 13
trials and 842 patients taking at least 7.5 mg/d prednisone
confirmed that bisphosphonates improve BMD [101].
The risk of spinal fractures was reduced 24%, although
this was not statistically significant (OR: 0.76; 95% CI:
0.37, 1.53) [101]. Data regarding other potential therapies
(eg, androgens, fluoride, intranasal calcitonin) are limited.
The role of these agents in the treatment or prevention
of CS-associated osteoporosis needs to be elucidated.
Peptic ulcer disease
The association of CS use and peptic ulcer disease
(PUD) is controversial. CS were associated with an in-
creased risk of PUD and gastrointestinal hemorrhage in
some studies [106], but a meta-analysis failed to find an
increased incidence of PUD among CS-treated patients
compared with controls [107]. Given the conflicting data,
the risk (if any) of PUD associated with CS appears to be
small. In our series, only one of 41 patients (2.5%) treated
with high-dose prednisone for 3 months developed a
peptic ulcer [8••]. Because endoscopies were only per-
formed for clinical indications, occult (asymptomatic)
disease could have been missed. The benefit of hista-
mine-2 antagonists or antacids to prevent PUD in CS-
treated patients has not been established. However, pa-
tients with a history of PUD or receiving concomitant
medications that increase the risk of PUD (eg, nonsteroi-
dal antiinflammatory agents) may benefit from prophy-
laxis with histamine-2 antagonists or proton pump inhibi-
tors. The use of prophylaxis in other low-risk populations
needs to be individualized.
Miscellaneous complications of corticosteroids
As outlined in Table 2, CS have protean side effects,
ranging from life-threatening opportunistic infections to
cosmetic changes (eg, Cushingoid features). For some pa-
tient populations (eg, age > 70, significant obesity, dia-
betes mellitus, serious psychiatric disease), the risk of CS
often exceeds the benefit. In such patients, we consider
alternative therapeutic modalities. Among CS-treated
patients, careful monitoring and patient education are
essential to identify complications to modify dose or
therapy at the earliest possible time.
Recent consensus statements and recommendations
for therapy
Given the potential for debilitating side effects with CS
therapy, recent editorials [108,109] and International
Consensus Statements [3,10] argue that high-dose CS
should be discouraged in IPF. Both consensus state-
ments [3,10] advocate an individualized approach to
treating IPF/UIP and acknowledge that not all patients
should be treated. For patients requiring treatment, both
societies recommend combining an immunosuppressive
agent (AZA or cyclophosphamide) with prednisone or
prednisolone (0.5 mg/kg/d for 4 weeks, with gradual
taper) [3,10]. When contraindications to CS exist, either
AZA or cyclophosphamide alone should be used. This is
a substantial departure from earlier regimens advocating
high-dose prednisone [20,23,110]. These recommenda-
tions are reasonable but have not been validated in sci-
entific trials. However, we agree that the era of high-dose
CS for prolonged periods has ended [109]. Given the
paucity of data, firm recommendations regarding indica-
tions, dose, or duration of CS treatment for UIP cannot
be given. We see no role for CS for patients with a
chronic course, extensive fibrosis, and absence of GGO
on HRCT or patients with specific contraindications.
However, a trial of CS (with or without concomitant AZA
or cyclophosphamide) is reasonable in patients with
GGO on HRCT, a subacute or deteriorating course,
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young age, and no contraindications to CS. In this con-
text, a trial of prednisone (40 mg/d for 4–8 weeks, with a
taper to 20 mg within 3–4 months) is reasonable. The
dose and duration need to be individualized depending
on the response and the presence or absence of side
effects. Therapy with CS should be continued beyond 3
or 4 months only when patients exhibit unequivocal and
objective responses to therapy. Subjective improvement
is not adequate to justify continuing a therapy with po-
tential cumulative toxicities.
Assessing response to therapy
Sequential physiologic studies are critical to assess the
response to therapy [3,10,111,112]. Optimal parameters
to follow the course of IPF have not been validated. We
use serial spirometry (eg, forced vital capacity and forced
expiratory volume in 1 second), 6-minute walk tests with
oximetry, and DLCO to monitor response to therapy.
Changes in forced vital capacity are usually adequate
to track the course of the disease; DLCO is more sensi-
tive but less reproducible. Six-minute walk tests
with oximetry are noninvasive, relatively inexpensive,
and invaluable in the initial assessment and longitudinal
assessment of IPF/UIP [113]. The value of formal car-
diopulmonary exercise testing is unproven. Criteria es-
tablished by the American Thoracic Society to define
physiologic improvement are reasonable (ie, 10% in to-
tal lung capacity or vital capacity, 15% increase in
DLCO,  4% increase in O2 saturation, or  4-mm in-
crease in arterial oxygen pressure during exercise [3].
The role of serial HRCT in evaluating response to
therapy has not been clarified.
Novel (future) agents
Unfortunately, current therapies for IPF based on alter-
ing the inflammatory component are marginally effec-
tive. The dictum nollo nocere is highly relevant, when
potentially toxic drugs such as CS or immunosuppressive
or cytotoxic agents are used for prolonged periods of
time. Judicious and careful use of these drugs, with ob-
jective monitoring, is mandatory. Major advances in the
treatment of IPF/UIP await the development of novel
therapies that prevent fibroproliferation and/or enhance
alveolar reepithelialization [58••]. Agents that have been
tested in pilot studies include pirfenidone (5-methyl-1-
phenyl-2-[1H]-pyridone) [114], N-acetylcysteine [115],
and interferon- [97]. Novel agents that inhibit fibrosis
in vitro or in animal models and are worthy of study in
future clinical trials include captopril [58••,116], plate-
let-activating factor receptor antagonists, inhibitors of
leukocyte integrins, cytokines or proteases [88,117], ke-
ratinocyte growth factor [118,119], relaxin [120], and lo-
vastatin [121].
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